overall mortality in dyslipidemia
Could we have https://doi.org/10.1371/journal.pone.0287923 reviewed or discussed? There is a bunch of all-cause mortality studies, seemingly associating dyslipidemia with reduced mortality. Most are non US based, while this recent paper is from the VETS (Veteran Exercise Testing Study). Not a field/literature I follow closely, but at first glance, authors seem credible, eg also published https://www.nejm.org/doi/pdf/10.1056/NEJMoa011858.1
GLYLO.... is it a no go?
I have been reading and listening to a few sources regarding “GLYLO”, a compound consisting of 5 supplements (alpha-lipoic acid, nicotinamide, piperine, pyridoxamine and thiamine… although it is actually pyridoxine in the real thing…). Anyway the scientist involved seems authentic (Dr Pankaj Kapahi of the BUCK institute). There is claimed evidence of improved insulin sensitivity, weight loss and life extension in both a worm and a mouse model, with a mechanism of action purported to be reduction of glycation. Obviously they are “planning” large mammal and human trials but in the meantime have rushed it to market…. Lots of claims (mostly unsubstantiated) about improved athletic performance, weight loss with a tendency to increase lean body mass, and improved glycaemic control. AND available on Amazon of course The scientist sounds genuine and interesting, and there is good evidence that glycation contributes to aging… Would you consider talking to him in a podcast? Is this just hype? Is he on the BUCK bandwagon?